Intranasal antisense therapy: preclinical models with a clinical future?

Area of Science:

• Biotechnology
• Pharmacology
• Respiratory Medicine

Background:

• Antisense strategies, including DNA oligonucleotides and RNA interference, are emerging as potential treatments for respiratory diseases.
• Chemical modifications and suitable formulations are crucial for enhancing the stability and clinical viability of antisense drugs.

Purpose of the Study:

• This review discusses the progress of DNA oligonucleotides and RNA interference for treating respiratory conditions.
• It highlights the challenges and opportunities in delivering these antisense drugs to target tissues.

Main Methods:

• Review of recent advancements in antisense oligonucleotide and RNA interference technologies.
• Analysis of formulation and chemical modification strategies for drug stability.
• Evaluation of nasal delivery as a route for respiratory antisense drug administration.

Main Results:

• Significant progress has been made in developing antisense strategies for respiratory diseases.
• Improved stability through formulation and chemical modification is advancing clinical application.
• Efficient delivery of antisense drugs to target respiratory tissues remains a major obstacle.

Conclusions:

• Antisense therapies hold potential for respiratory disease treatment.
• Overcoming delivery challenges is critical for the successful clinical translation of these innovative therapies.
• Nasal delivery presents a promising, yet challenging, route for antisense drug targeting in the respiratory system.